Phase 1b clinical trial of AOBiome provides B244 treatment for first young patient

AOBioMes, Inc("AOBiome), a leading clinical stage microbiotic development focused on innovative treatments for skin diseases, migraines, hypertension and other systemic diseases
(http://, today announced the use of its main candidateproduct(http://B244 in its Phase 1b ClinicalTrial(http://to treat the first young patientwithwith severe dysplasia (eczema)The clinical trial was a Phase 1b study of B244 openness, diversity, which was treated with the first external beneficial ammonia oxidizing bacteria ("AOB") to assess the safety and tolerance of AOB (twice a day for 28 days) for 36 young patients aged 2 to 17 with mild to moderate asexual dermatitisTodd Krueger, President and CEO of AOBiome, said, "Due to the high incidence of asexual dermatitis in young patients and the limited safety and effective treatment for this sensitive population, new treatments for this condition have a significantmedical(http://demandWe look forward to publishing the results of this study in the second half of 2019in the United States, 13% (or 9.6 million) of children under the age of 18 have eczemaAbout one-third of them suffer from moderate to severe eczemaIn addition, a recent study showed that many adolescentchildren with asexual dermatitis are more likely to develop a number of diseases later in life, with studies showing that 43 per cent of children who had severe asexual dermatitis before the age of 8 develop asthma later and 45 per cent with allergic rhinitis later in life"Our goal is to alleviate myolytic dermatitis-related conditions, to provide a dual treatment using the anti-inflammatory capacity of AOB's nitric oxide vector, and its ability to reduce pathogenic bacteria," said Judith Ng Cashin, M.D., Chief Medical Officer of AOBiomeExisting treatments for asexual dermatitis can cause side effects such as tingling, burning and thinning of the skin, especially in young patientsThe innovation of B244 represents a new treatment opportunity that meets the huge market demand and affects the lives of patientsin addition to ongoing pediatric studies, AOBiome is currently conducting Phase II clinical trials on B244 for the treatment of adult asexual dermatitis, with critical results expected in 2019The line of ammonia oxidation bacteriaAOBiome on ammonia oxidation bacteria (AOB) includes a
patented(http://, intellectual property, for external use and nasal administration using a single strain, nitritemThis product line is designed to reactivate the skin or nasal microbiome with ammonia oxidizing bacteriaOnce this method is used, ammonia oxidation bacteria can consume ammonia and produce nitrites and nitric oxide, which controls inflammation and blood vessel dilationAbout AOBiomes, Inc.
　　AOBio Therapeuticmes, Inc., a life sciences company based in Cambridge, Massachusetts, focuses on developing microbiomic-based therapies to change the of health (http:// in humans and to apply local, nasal and systemic inflammation The company was founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT chemical engineer David Whitlock AOBiome is accelerating the expansion of different clinical stage candidates The company's portfolio includes a number of clinically completed phase II studies for people with common acne or acne, Phase 1b studies for the treatment of eczema (specialty dermatitis) in children, Phase II studies for the treatment of adult eczema (specialty dermatitis), phase II studies for the treatment of migraines, clinical trials for allergic rhinitis 1b/2a, and several early preclinical projects for various types of inflammation